Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
Impact of Oxidative Stress on the Heart and VasculatureThomas Münzel, Jason C. Kovacic, Giovanni G. Camici et al.|Journal of the American College of Cardiology|2017Cited by 586
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344
The continuous heart failure spectrum: moving beyond an ejection fraction classificationFilippos Triposkiadis, Gilles W. De Keulenaer, Javed Butler et al.|European Heart Journal|2019Cited by 258
Current Management of Patients with Severe Acute Peripartum Cardiomyopathy: Practical Guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum CardiomyopathyJohann Bauersachs, Karen Sliwa, Mattia Arrigo et al.|European Journal of Heart Failure|2016Cited by 248